These results are consistent with recent reports showing that loss of CIC imparts resistance to MAPK and EGFR inhibitors in various cancer‐derived cell lines with activating mutations in upstream members of the pathway, including KRAS, NRAS, BRAF, and EGFR 23, 24. The gene discussed is KRAS; the disease is cancer.